What Does the Evidence Actually Say About Wegovy? A Guide for Patients in Newport

There is a growing body of evidence behind injectable weight loss treatments, but with several options now available, knowing which one to choose can feel confusing. For patients in Newport who have been researching their options, this guide focuses specifically on Wegovy: how it compares to other treatments, what the clinical evidence actually shows, and why the right choice ultimately comes down to your individual health profile rather than which medication has the most attention.

Making an informed decision before your first consultation puts you in the best possible position to get the most from treatment from day one.

To speak with our team and find out which treatment may be right for you, contact us at info@mayberrypharmacy.co.uk or book a consultation online today.

 

What Is Wegovy and What Makes It Different?

 

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone involved in appetite regulation and blood sugar control. It reduces hunger, slows gastric emptying, and helps patients feel fuller for longer. It is administered once weekly via a pre-filled injection pen and is licensed in the UK for weight management alongside diet and physical activity.

According to the NHS, Wegovy is a prescription-only medicine for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. It should be used under medical supervision as part of a structured weight management programme.

Wegovy differs from older treatments by targeting appetite-regulating hormones and has been studied extensively in large clinical trials demonstrating significant weight loss.

lose weight mounjaro

What Does the Clinical Evidence Show?

 

The STEP clinical trial programme provided the data behind Wegovy’s approval. The key findings are summarised below:

TrialPopulationDurationAverage Weight Loss (Wegovy)
STEP 1Adults with obesity, no type 2 diabetes68 weeks~14.9%
STEP 2Adults with obesity and type 2 diabetes68 weeks~9.6%
STEP 3Adults with obesity plus intensive behavioural therapy68 weeks~16%
STEP 4Adults who continued vs stopped treatment after 20 weeks48 weeksContinued: further ~7.9% vs regain of ~6.9% in placebo group

These figures represent averages from large trial populations. Individual results will always vary based on starting weight, lifestyle factors, and how consistently treatment is maintained.

 

What Affects How Well Wegovy Works for You?

 

Your starting BMI and health profile

Patients without type 2 diabetes tend to achieve stronger average weight loss on Wegovy than those with the condition, as the STEP trial data shows. Your broader health profile, including any medications you take, will be assessed during your consultation to give you the most accurate picture of what to expect.

Lifestyle changes alongside treatment

The STEP 3 trial, which combined Wegovy with intensive behavioural therapy, achieved the highest average weight loss of the series at around 16%. This underlines how significantly diet, activity, and behavioural support can amplify the medication’s effects.

Continuing treatment beyond the early months

The STEP 4 trial demonstrated clearly that stopping Wegovy after an initial period of success leads to significant weight regain. Patients who continued treatment maintained and extended their results, highlighting the importance of long-term commitment to the programme.

Dose progression and tolerability

Patients who are able to progress through the full dose escalation schedule and maintain the 2.4 mg maintenance dose tend to achieve stronger results. The gradual dose increase is designed to support tolerability, and your prescriber will guide you through each step.

If you are also weighing up Wegovy against Mounjaro, our detailed comparison of Mounjaro vs Wegovy breaks down the clinical differences between the two treatments to help you have a more informed conversation at your consultation. For patients who have already tried one treatment and are considering switching, our guide on switching from Mounjaro to Wegovy covers what the transition involves.

 

Is Wegovy Right for You? Key Eligibility Criteria

 

Before any prescription is issued, a thorough consultation is carried out to confirm suitability. Wegovy may be appropriate for adults who:

  • Have a BMI of 30 or above
  • Have a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, raised cholesterol, or type 2 diabetes
  • Do not have contraindications including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Are not pregnant, planning a pregnancy in the near term, or breastfeeding
  • Are committed to making appropriate dietary and lifestyle changes alongside treatment

 

What the Treatment Journey Looks Like

 

From consultation to maintenance dose

  • Initial consultation to assess eligibility, review medical history, and discuss treatment expectations
  • Prescription issued if suitable, with a starting dose of 0.25 mg
  • Dose increases every four weeks over approximately five months until the 2.4 mg maintenance dose is reached
  • Regular check-ins throughout treatment to monitor progress, manage any side effects, and adjust the plan as needed

Practical preparation before starting

  • Prepare a refrigerator storage space at 2 degrees C to 8 degrees C for your medication
  • Choose a consistent weekly injection day that fits your schedule
  • Review your current medications with your pharmacist to identify any potential interactions
  • Set realistic expectations: the most significant results typically develop over several months, not weeks

weight loss clinic

 

Frequently Asked Questions

 

Is Wegovy available in Newport?

Yes. Our Newport branch offers private Wegovy consultations and prescriptions. Online booking is available for your convenience.

How does Wegovy differ from Ozempic?

Both Wegovy and Ozempic contain semaglutide, but they are different licensed products. Ozempic is licensed for blood sugar management in type 2 diabetes, while Wegovy is licensed specifically for chronic weight management. The doses also differ, with Wegovy reaching a higher maintenance dose of 2.4 mg.

Do I need a GP referral to access Wegovy?

No referral is needed. You can book directly with our team and we will carry out a full suitability assessment before any prescription is issued.

How long before I see results with Wegovy?

Many patients notice appetite changes within the first two to four weeks. Visible weight loss typically becomes more apparent from weeks four to eight, with the most significant cumulative results developing over several months of consistent treatment at the maintenance dose.

What is the difference between Wegovy and Mounjaro?

Wegovy contains semaglutide and acts on one hormone pathway (GLP-1), while Mounjaro contains tirzepatide and acts on two pathways (GIP and GLP-1). Both are effective licensed treatments, but they work differently and suit different patient profiles. Our team can help you understand which may be more appropriate for you during a consultation.

 

Expert Weight Loss Support in Newport

 

Choosing the right weight loss treatment is a significant decision, and having access to clear, evidence-based information makes that decision much easier. At Mayberry Pharmacy, our team provides honest guidance, thorough clinical assessments, and ongoing support throughout your treatment journey.

We serve patients across South Wales from our branches in Newport, Caerphilly, Blackwood, Crumlin, Pontypool, Trevethin, and Penarth.

Get in touch at info@mayberrypharmacy.co.uk or book your weight loss consultation online today.

Please note: This blog is intended as a general guide only. It does not replace professional medical advice. For guidance tailored to your individual health needs and circumstances, please visit us in branch or reach out to our team directly.
☑ Clinically Reviewed by Pharmacy Mentor
A pharmacist reviews the content to help ensure medicines are presented responsibly and that patient-facing health information is accurate, appropriate, and aligned with current clinical guidance.
Last reviewed: 30 April 2026
Written on behalf of Mayberry Pharmacy by Pharmacy Mentor.